Certain biological factors, including tumor grade, comedonecrosis, tumor size, hormone receptor-negative status, and HER2 positive status, are known to predict a greater risk of disease recurrence or progression but do not accurately identify the group of patients at risk of death from their DCIS and do not predict the therapy that could prevent that event 2. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.